Glucocorticoids in the regulation of transcription factors that control cytokine synthesis

Cytokine and Growth Factor Reviews

Volumn 18, Issue 1-2, 2007, Pages 45-56

  Liberman, Ana C ^a   Druker, Jimena ^a   Perone, Marcelo J ^a   Arzt, Eduardo ^a  

^a INSTITUTO DE FISIOLOGÍA   (Argentina)

Author keywords

Cytokine receptors; Cytokines; Glucocorticoids; Molecular interaction; Transcription factors

Indexed keywords

CYTOKINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR;

ARTICLE; CHEMICAL INTERACTION; CHROMATIN; CROSS LINKING; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; GLUCOCORTICOIDS; HUMANS; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 33947196913     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2007.01.005     Document Type: Article

References (99)

1. Ashwell J.D., Lu F.W., and Vacchio M.S. Glucocorticoids in T-cell development and function. Annu Rev Immunol 18 (2000) 309-345
2. Sapolsky R.M., Romero L.M., and Munck A.U. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 21 (2000) 55-89
3. Besedovsky H.O., and del Rey A. Immune-neuroendocrine circuits: integrative role of cytokines. Front Neuroendocrinol 13 (1992) 61-94
4. Boumpas D.T., Chrousos G.P., Wilder R.L., Cupps T.R., and Balow J.E. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119 (1993) 1198-1208
5. Barnes P.J., and Adcock I.M. Transcription factors and asthma. Eur Respir J 12 (1998) 221-234
6. Swartz S.L., and Dluhy R.G. Corticosteroids: clinical pharmacology and therapeutic use. Drugs 16 (1978) 238-255
7. De Bosscher K., Vanden Berghe W., and Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 109 (2000) 16-22
8. De Bosscher K., Vanden Berghe W., and Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24 (2003) 488-522
9. Drouin J., Maira M., and Philips A. Novel mechanism of action for Nur77 and antagonism by glucocorticoids: a convergent mechanism for CRH activation and glucocorticoid repression of POMC gene transcription. J Steroid Biochem Mol Biol 65 (1998) 59-63
10. Abbas A.K., Murphy K.M., and Sher A. Functional diversity of helper T lymphocytes. Nature 383 (1996) 787-793
11. Dinarello C.A., and Mier J.W. Lymphokines. N Engl J Med 317 (1987) 940-945
12. Paul W.E., and Seder R.A. Lymphocyte responses and cytokines. Cell 76 (1994) 241-251
13. Wang M., Tan Z., Zhang R., Kotenko S.V., and Liang P. Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem 277 (2002) 7341-7347
14. Dinarello C.A. The interleukin-1 family: 10 years of discovery. FASEB J 8 (1994) 1314-1325
15. Reed J.C., Abidi A.H., Alpers J.D., Hoover R.G., Robb R.J., and Nowell P.C. Effect of cyclosporin A and dexamethasone on interleukin 2 receptor gene expression. J Immunol 137 (1986) 150-154
16. Gillis S., Crabtree G.R., and Smith K.A. Glucocorticoid-induced inhibition of T-cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation. J Immunol 123 (1979) 1624-1631
17. Boumpas D.T., Anastassiou E.D., Older S.A., Tsokos G.C., Nelson D.L., and Balow J.E. Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription. J Clin Invest 87 (1991) 1739-1747
18. Mozo L., Gayo A., Suarez A., Rivas D., Zamorano J., and Gutierrez C. Glucocorticoids inhibit IL-4 and mitogen-induced IL-4R alpha chain expression by different posttranscriptional mechanisms. J Allergy Clin Immunol 102 (1998) 968-976
19. So E.Y., Kim S.H., Park H.H., Cho B.S., and Lee C.E. Corticosteroid inhibits IL-4 signaling through down-regulation of IL-4 receptor and STAT6 activity. FEBS Lett 518 (2002) 53-59
20. Wu C.Y., Wang K., McDyer J.F., and Seder R.A. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J Immunol 161 (1998) 2723-2730
21. Mori S., Murakami-Mori K., and Bonavida B. Dexamethasone enhances expression of membrane and soluble interleukin-6 receptors by prostate carcinoma cell lines. Anticancer Res 18 (1998) 4403-4408
22. Hawrylowicz C.M., Guida L., and Paleolog E. Dexamethasone up-regulates granulocyte-macrophage colony-stimulating factor receptor expression on human monocytes. Immunology 83 (1994) 274-280
23. Sapi E., Flick M.B., Gilmore-Hebert M., Rodov S., and Kacinski B.M. Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human breast carcinoma cells by glucocorticoids. Oncogene 10 (1995) 529-542
24. Lee H.C., Shibata H., Ogawa S., Maki K., and Ikuta K. Transcriptional regulation of the mouse IL-7 receptor alpha promoter by glucocorticoid receptor. J Immunol 174 (2005) 7800-7806
25. Kovalovsky D., Paez Pereda M., Sauer J., Perez Castro C., Nahmod V.E., Stalla G.K., et al. The Th1 and Th2 cytokines IFN-gamma and IL-4 antagonize the inhibition of monocyte IL-1 receptor antagonist by glucocorticoids: involvement of IL-1. Eur J Immunol 28 (1998) 2075-2085
26. Arzt E., Sauer J., Pollmacher T., Labeur M., Holsboer F., Reul J.M., et al. Glucocorticoids suppress interleukin-1 receptor antagonist synthesis following induction by endotoxin. Endocrinology 134 (1994) 672-677
27. Brown E.A., Dare H.A., Marsh C.B., and Wewers M.D. The combination of endotoxin and dexamethasone induces type II interleukin 1 receptor (IL-1rII) in monocytes: a comparison to interleukin 1 beta (IL-1beta) and interleukin 1 receptor antagonist (IL-1ra). Cytokine 8 (1996) 828-836
28. Visser J., and Nagelkerken L. Expression of the IL-10 receptor on human monocytes is moderately suppressed by glucocorticoids. Int Immunopharmacol 2 (2002) 1491-1493
29. Visser J.T. Sparing interleukin-10 receptor expression by glucocorticoids is a prerequisite for the synergistic immunosuppressive effects of interleukin-10 and glucocorticoids. Transplantation 76 (2003) 1534-1535 (author reply 1535)
30. Romagnani S. The Th1/Th2 paradigm. Immunol Today 18 (1997) 263-266
31. Glimcher L.H., and Murphy K.M. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev 14 (2000) 1693-1711
32. Liu J., and Beller D.I. Distinct pathways for NF-kappa B regulation are associated with aberrant macrophage IL-12 production in lupus- and diabetes-prone mouse strains. J Immunol 170 (2003) 4489-4496
33. Liberman A.C., Refojo D., and Arzt E. Cytokine signaling/transcription factor cross-talk in T-cell activation and Th1-Th2 differentiation. Arch Immunol Ther Exp (Warsz) 51 (2003) 351-365
34. Refojo D., Liberman A.C., Giacomini D., Carbia Nagashima A., Graciarena M., Echenique C., et al. Integrating systemic information at the molecular level: cross-talk between steroid receptors and cytokine signaling on different target cells. Ann NY Acad Sci 992 (2003) 196-204
35. Kovalovsky D., Refojo D., Holsboer F., and Arzt E. Molecular mechanisms and Th1/Th2 pathways in corticosteroid regulation of cytokine production. J Neuroimmunol 109 (2000) 23-29
36. Helmberg A., Auphan N., Caelles C., and Karin M. Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J 14 (1995) 452-460
37. Jonat C., Rahmsdorf H.J., Park K.K., Cato A.C., Gebel S., Ponta H., et al. Antitumor promotion and anti-inflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62 (1990) 1189-1204
38. Schule R., Rangarajan P., Kliewer S., Ransone L.J., Bolado J., Yang N., et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 62 (1990) 1217-1226
39. Ray A., and Prefontaine K.E. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 91 (1994) 752-756
40. Wissink S., van Heerde E.C., vand der Burg B., and van der Saag P.T. A dual mechanism mediates repression of NF-kappa B activity by glucocorticoids. Mol Endocrinol 12 (1998) 355-363
41. Scheinman R.I., Gualberto A., Jewell C.M., Cidlowski J.A., and Baldwin Jr. A.S. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 15 (1995) 943-953
42. Caldenhoven E., Liden J., Wissink S., Van de Stolpe A., Raaijmakers J., Koenderman L., et al. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 9 (1995) 401-412
43. Scheinman R.I., Cogswell P.C., Lofquist A.K., and Baldwin Jr. A.S. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270 (1995) 283-286
44. Auphan N., DiDonato J.A., Rosette C., Helmberg A., and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270 (1995) 286-290
45. Costas M.A., Muller Igaz L., Holsboer F., and Arzt E. Transrepression of NF-kappa B is not required for glucocorticoid-mediated protection of TNF-alpha-induced apoptosis on fibroblasts. Biochim Biophys Acta 1499 (2000) 122-129
46. Mukaida N., Morita M., Ishikawa Y., Rice N., Okamoto S., Kasahara T., et al. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem 269 (1994) 13289-13295
47. Nissen R.M., and Yamamoto K.R. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 14 (2000) 2314-2329
48. Vacca A., Felli M.P., Farina A.R., Martinotti S., Maroder M., Screpanti I., et al. Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 175 (1992) 637-646
49. Chen R., Burke T.F., Cumberland J.E., Brummet M., Beck L.A., Casolaro V., et al. Glucocorticoids inhibit calcium- and calcineurin-dependent activation of the human IL-4 promoter. J Immunol 164 (2000) 825-832
50. Mori A., Kaminuma O., Suko M., Inoue S., Ohmura T., Hoshino A., et al. Two distinct pathways of interleukin-5 synthesis in allergen-specific human T-cell clones are suppressed by glucocorticoids. Blood 89 (1997) 2891-2900
51. Jee Y.K., Gilmour J., Kelly A., Bowen H., Richards D., Soh C., et al. Repression of interleukin-5 transcription by the glucocorticoid receptor targets GATA3 signaling and involves histone deacetylase recruitment. J Biol Chem 280 (2005) 23243-23250
52. Cippitelli M., Sica A., Viggiano V., Ye J., Ghosh P., Birrer M.J., et al. Negative transcriptional regulation of the interferon-gamma promoter by glucocorticoids and dominant negative mutants of c-Jun. J Biol Chem 270 (1995) 12548-12556
53. Tao Y., Williams-Skipp C., and Scheinman R.I. Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis. J Biol Chem 276 (2001) 2329-2332
54. von Laue S., Finidori J., Maamra M., Shen X.Y., Justice S., Dobson P.R., et al. Stimulation of endogenous GH and interleukin-6 receptors selectively activates different Jaks and Stats, with a Stat5 specific synergistic effect of dexamethasone. J Endocrinol 165 (2000) 301-311
55. Bianchi M., Meng C., and Ivashkiv L.B. Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids. Proc Natl Acad Sci USA 97 (2000) 9573-9578
56. Biola A., Andreau K., David M., Sturm M., Haake M., Bertoglio J., et al. The glucocorticoid receptor and STAT6 physically and functionally interact in T-lymphocytes. FEBS Lett 487 (2000) 229-233
57. Lechner J., Welte T., and Doppler W. Mechanism of interaction between the glucocorticoid receptor and Stat5: role of DNA-binding. Immunobiology 198 (1997) 112-123
58. Pfitzner E., Jahne R., Wissler M., Stoecklin E., and Groner B. p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response. Mol Endocrinol 12 (1998) 1582-1593
59. Zhang Z., Jones S., Hagood J.S., Fuentes N.L., and Fuller G.M. STAT3 acts as a co-activator of glucocorticoid receptor signaling. J Biol Chem 272 (1997) 30607-30610
60. Aittomaki S., Pesu M., Groner B., Janne O.A., Palvimo J.J., and Silvennoinen O. Cooperation among Stat1, glucocorticoid receptor, and PU.1 in transcriptional activation of the high-affinity Fc gamma receptor I in monocytes. J Immunol 164 (2000) 5689-5697
61. Fahey A.J., Robins R.A., Kindle K.B., Heery D.M., and Constantinescu C.S. Effects of glucocorticoids on STAT4 activation in human T cells are stimulus-dependent. J Leukoc Biol 80 (2006) 133-144
62. Franchimont D., Galon J., Gadina M., Visconti R., Zhou Y., Aringer M., et al. Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol 164 (2000) 1768-1774
63. Ramirez F. Glucocorticoids induce a Th2 response in vitro. Dev Immunol 6 (1998) 233-243
64. Blotta M.H., DeKruyff R.H., and Umetsu D.T. Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol 158 (1997) 5589-5595
65. Zhang D.H., Cohn L., Ray P., Bottomly K., and Ray A. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem 272 (1997) 21597-21603
66. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., and Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100 (2000) 655-669
67. Costas M., Trapp T., Pereda M.P., Sauer J., Rupprecht R., Nahmod V.E., et al. Molecular and functional evidence for in vitro cytokine enhancement of human and murine target cell sensitivity to glucocorticoids. TNF-alpha priming increases glucocorticoid inhibition of TNF-alpha-induced cytotoxicity/apoptosis. J Clin Invest 98 (1996) 1409-1416
68. Orti E., Mendel D.B., Smith L.I., and Munck A. Agonist-dependent phosphorylation and nuclear dephosphorylation of glucocorticoid receptors in intact cells. J Biol Chem 264 (1989) 9728-9731
69. Almlof T., Wright A.P., and Gustafsson J.A. Role of acidic and phosphorylated residues in gene activation by the glucocorticoid receptor. J Biol Chem 270 (1995) 17535-17540
70. Webster J.C., Jewell C.M., Bodwell J.E., Munck A., Sar M., and Cidlowski J.A. Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J Biol Chem 272 (1997) 9287-9293
71. Hittelman A.B., Burakov D., Iniguez-Lluhi J.A., Freedman L.P., and Garabedian M.J. Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J 18 (1999) 5380-5388
72. Rogatsky I., Logan S.K., and Garabedian M.J. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci USA 95 (1998) 2050-2055
73. Itoh M., Adachi M., Yasui H., Takekawa M., Tanaka H., and Imai K. Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated phosphorylation. Mol Endocrinol 16 (2002) 2382-2392
74. Irusen E., Matthews J.G., Takahashi A., Barnes P.J., Chung K.F., and Adcock I.M. p38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 109 (2002) 649-657
75. Szatmary Z., Garabedian M.J., and Vilcek J. Inhibition of glucocorticoid receptor-mediated transcriptional activation by p38 mitogen-activated protein (MAP) kinase. J Biol Chem 279 (2004) 43708-43715
76. DeFranco D.B., Qi M., Borror K.C., Garabedian M.J., and Brautigan D.L. Protein phosphatase types 1 and/or 2A regulate nucleocytoplasmic shuttling of glucocorticoid receptors. Mol Endocrinol 5 (1991) 1215-1228
77. Rider L.G., Hirasawa N., Santini F., and Beaven M.A. Activation of the mitogen-activated protein kinase cascade is suppressed by low concentrations of dexamethasone in mast cells. J Immunol 157 (1996) 2374-2380
78. Caelles C., Gonzalez-Sancho J.M., and Munoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 11 (1997) 3351-3364
79. Gonzalez M.V., Gonzalez-Sancho J.M., Caelles C., Munoz A., and Jimenez B. Hormone-activated nuclear receptors inhibit the stimulation of the JNK and ERK signalling pathways in endothelial cells. FEBS Lett 459 (1999) 272-276
80. Swantek J.L., Cobb M.H., and Geppert T.D. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol 17 (1997) 6274-6282
81. Sakai A., Han J., Cato A.C., Akira S., and Li J.D. Glucocorticoids synergize with IL-1beta to induce TLR2 expression via MAP kinase phosphatase-1-dependent dual Inhibition of MAPK JNK and p38 in epithelial cells. BMC Mol Biol 5 (2004) 2
82. Biola A., Lefebvre P., Perrin-Wolff M., Sturm M., Bertoglio J., and Pallardy M. Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving STAT5 (signal transducer and activator of transcription 5), but not AP-1. Mol Endocrinol 15 (2001) 1062-1076
83. Lasa M., Abraham S.M., Boucheron C., Saklatvala J., and Clark A.R. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 22 (2002) 7802-7811
84. Orphanides G., and Reinberg D. RNA polymerase II elongation through chromatin. Nature 407 (2000) 471-475
85. Margueron R., Trojer P., and Reinberg D. The key to development: interpreting the histone code?. Curr Opin Genet Dev 15 (2005) 163-176
86. Orphanides G., and Reinberg D. A unified theory of gene expression. Cell 108 (2002) 439-451
87. Takemoto N., Arai K., and Miyatake S. Cutting edge: the differential involvement of the N-finger of GATA-3 in chromatin remodeling and transactivation during Th2 development. J Immunol 169 (2002) 4103-4107
88. Shoemaker J., Saraiva M., and O'Garra A. GATA-3 directly remodels the IL-10 locus independently of IL-4 in CD4+ T cells. J Immunol 176 (2006) 3470-3479
89. Qiu Y., Zhao Y., Becker M., John S., Parekh B.S., Huang S., et al. HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol Cell 22 (2006) 669-679
90. Ito K., Yamamura S., Essilfie-Quaye S., Cosio B., Ito M., Barnes P.J., et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappa B suppression. J Exp Med 203 (2006) 7-13
91. Glass C.K., and Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14 (2000) 121-141
92. Ostlund Farrants A.K., Blomquist P., Kwon H., and Wrange O. Glucocorticoid receptor-glucocorticoid response element binding stimulates nucleosome disruption by the SWI/SNF complex. Mol Cell Biol 17 (1997) 895-905
93. Fletcher T.M., Xiao N., Mautino G., Baumann C.T., Wolford R., Warren B.S., et al. ATP-dependent mobilization of the glucocorticoid receptor during chromatin remodeling. Mol Cell Biol 22 (2002) 3255-3263
94. Deroo B.J., and Archer T.K. Glucocorticoid receptor activation of the I kappa B alpha promoter within chromatin. Mol Biol Cell 12 (2001) 3365-3374
95. Carbia-Nagashima A., and Arzt E. Intracellular proteins and mechanisms involved in the control of gp130/JAK/STAT cytokine signaling. IUBMB Life 56 (2004) 83-88
96. Bossis G., Malnou C.E., Farras R., Andermarcher E., Hipskind R., Rodriguez M., et al. Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol 25 (2005) 6964-6979
97. Gill G. Something about SUMO inhibits transcription. Curr Opin Genet Dev 15 (2005) 536-541
98. Le Drean Y., Mincheneau N., Le Goff P., and Michel D. Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. Endocrinology 143 (2002) 3482-3489
99. Desterro J.M., Rodriguez M.S., and Hay R.T. SUMO-1 modification of IkappaBalpha inhibits NF-kappa B activation. Mol Cell 2 (1998) 233-239